Allogeneic bone marrow transplantation for multiple myeloma.
Seventeen patients received marrow transplants from their HLA-matched, MLC-negative, sibling donors. Nine patients had progressive disease not responding to conventional treatments, while the other 8 patients were rated as responders. The most frequently used conditioning regimen consisted of total body irradiation and high-dose multi-agent chemotherapy with cyclophosphamide plus either oral melphalan (5 cases) or BCNU (1 case) on both these drugs (7 cases). Twelve patients were valuable for response to BTM: 7 of them (6 responders and 1 with advanced refractory MM) entered complete remission, while 5 had sustained decrease in tumor mass that ranged between 72% and 93%. Eleven patients died of transplant-related causes, 1 of them with signs of progressive disease. The remaining 6 patients are alive and 5 of them maintain a complete remission status 4 to 67 (median 36) months after BMT.
Tura
S
S
Institute of Haematology, L. e A. Seràgnoli, University of Bologna, Italy.
Cavo
M
M
Rosti
G
G
Bandini
G
G
Gobbi
M
M
Grimaldi
M
M
Miggiano
M C
MC
Albertazzi
L
L
Bonelli
M A
MA
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D011658:Pulmonary Fibrosis / Q000209:etiology; D014184:Transplantation, Homologous